Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Dysplasia 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Glioblastoma 1

Interventions

Temozolomide 44Radiotherapy 16Bevacizumab 9Surgical Procedures, Operative 5Carmustine 5pembrolizumab 4Lomustine 4Drug Therapy 4Sunitinib 3Standard of Care 3Radiation 3Procarbazine 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3Chlorotoxin 3Carboplatin 3Blood Specimen Collection 3tislelizumab 2fludarabine 2camrelizumab 2Radiosurgery 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Hyperbaric Oxygenation 2Ethanol 2Cyclophosphamide 2Chemotherapy, Adjuvant 2CT-322 2Bortezomib 2Aminolevulinic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Glioblastoma × efineptakin alfa × Clear all
NCT05191784 2023-06-12

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Genexine, Inc.

Phase 2 Unknown
20 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡